The U.S. Food and Drug Administration (FDA) granted IN-001 Fast Track designation for anaphylaxis in July 2024. This designation allows for a faster regulatory review process, supporting Insignis’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback